세계의 장내 미생물 시장 보고서(2025년)
Gut Microbiota Global Market Report 2025
상품코드 : 1751010
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

장내 미생물 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 예측 기간의 주요 동향으로는 AI를 활용한 마이크로바이옴 해석, 차세대 시퀀서의 진보, CRISPR을 활용한 장내 미생물 편집, 스마트 프로바이오틱스 딜리버리 시스템의 개발, 웨어러블 장내 건강 모니터링 디바이스의 출현 등을 들 수 있습니다.

맞춤형 의료에 대한 수요 증가가 향후 수년간 장내 미생물 시장 성장을 가속할 것으로 예측됩니다. 유전체학와 생명공학의 진보로 유전자 프로파일을 보다 정확하게 확인할 수 있게 되어, 보다 적은 보다 효과적이고 부작용이 적은 치료가 가능해지므로, 맞춤형 의료에 대한 수요가 높아지고 있습니다. 개인화된 의료는 장내 박테리아총에 특히 유익합니다. 비영리 단체인 맞춤형 의료연합(PMC)은 미국 식품의약국(FDA)이 2023년에 26개의 새로운 개별화의약품을 승인했다고 보고했습니다.

장내 미생물 시장의 주요 기업은 다양한 소화기 질환과 장애에 대처하기 위해 경구 투여 분변 미생물총 등의 혁신적인 솔루션에 주력하고 있습니다. 예를 들어, 2023년 4월, 미국의 마이크로 바이옴 치료제 플랫폼 회사인 Celes Ceraputics는 18 세 이상의 성인에서 Crostoridiodes Difissil(C. difficile) 감염증(CDI)의 재발 예방을 목적으로 한 최초의 경구 대변 미생물 제제인 Vowst의 FDA 승인을 취득했습니다. Vowst의 경구용 제형은 치료 순응도를 개선하고 의료 분야에서 마이크로바이옴 기반 치료의 광범위한 채택을 촉진할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Gut microbiota refers to the diverse community of microorganisms, including bacteria, viruses, fungi, and other microbes, that inhabit the gastrointestinal tract. These microbes play a crucial role in digestion, immune function, and overall health by influencing metabolism and offering protection against harmful pathogens.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary product types in the gut microbiota market include prebiotics, probiotics, drugs, supplements, and other products. Prebiotics are non-digestible food components, mainly dietary fibers, that serve as food for beneficial bacteria in the gut. These products are distributed through various channels such as pharmacies, drugstores, online retail, health food stores, supermarkets, hypermarkets, and specialty stores. They are used for a range of applications including digestive health, immune health, weight management, mental health, and cardiovascular health, and cater to different end-users, including adults, children, and the elderly.

The gut microbiota market research report is one of a series of new reports from The Business Research Company that provides gut microbiota market statistics, including gut microbiota industry global market size, regional shares, competitors with a gut microbiota market share, detailed gut microbiota market segments, market trends and opportunities, and any further data you may need to thrive in the gut microbiota industry. This gut microbiota market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gut microbiota market size has grown rapidly in recent years. It will grow from$0.55 billion in 2024 to $0.65 billion in 2025 at a compound annual growth rate (CAGR) of 18.5%. The growth during the historic period can be attributed to the discovery of probiotics and prebiotics, the rise in gastrointestinal disorders, increasing interest in functional foods, the growing use of antibiotics, and heightened awareness of the gut-brain axis.

The gut microbiota market size is expected to see rapid growth in the next few years. It will grow to$1.27 billion in 2029 at a compound annual growth rate (CAGR) of 18.2%. The growth in the forecast period can be attributed to the expansion of personalized nutrition, rising demand for microbiome-based therapeutics, growth in functional and fermented foods, and regulatory support for probiotics and prebiotics. Major trends in the forecast period include AI-driven microbiome analysis, advancements in next-generation sequencing, CRISPR-based gut microbiota editing, development of smart probiotic delivery systems, and the emergence of wearable gut health monitoring devices.

The increasing demand for personalized medicine is expected to drive the growth of the gut microbiota market in the coming years. Personalized medicine involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize health outcomes and improve care. The demand for personalized medicine is growing as advancements in genomics and biotechnology enable more precise identification of genetic profiles, allowing for treatments that are better targeted, more effective, and have fewer side effects. Personalized medicine is particularly beneficial for gut microbiota, as it allows for the customization of treatments based on an individual's unique microbiome composition, optimizing gut health and improving outcomes for digestive and metabolic disorders. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase compared to the 12 approvals in 2022. As such, the growing demand for personalized medicine is driving the expansion of the gut microbiota market.

Leading companies in the gut microbiota market are focusing on innovative solutions, such as orally administered fecal microbiota, to address various gastrointestinal diseases and disorders. Orally administered fecal microbiota involves taking a capsule or pill containing beneficial bacteria from a healthy donor's stool to restore balance to the gut microbiome. For example, in April 2023, Seres Therapeutics Inc., a US-based microbiome therapeutics platform company, received FDA approval for Vowst, the first oral fecal microbiota product designed to prevent recurrent Clostridioides difficile (C. difficile) infection (CDI) in adults aged 18 and older. Vowst is intended for use after antibacterial treatment for recurrent CDI, providing a more accessible, patient-friendly alternative to traditional fecal microbiota transplants, which are usually administered via colonoscopy or enema. The oral formulation of Vowst may improve treatment adherence and promote the broader adoption of microbiome-based therapies in healthcare.

In April 2023, Archer-Daniels-Midland Company (ADM), a US-based food processing company, partnered with Brightseed to develop scientifically backed synbiotic products that support gut microbiome health. This collaboration leverages Brightseed's AI-driven molecular insights to create evidence-based formulations that aim to enhance immune function, metabolic health, and mental well-being. By combining ADM's nutrition expertise with Brightseed's AI technology, the partnership is focused on advancing gut health solutions grounded in cutting-edge science. Brightseed, a US-based biotechnology company, specializes in gut microbiome research through its proprietary AI platform.

Major players in the gut microbiota market are Danone S.A., DuPont de Nemours Inc., International Flavors & Fragrances Inc., Seres Therapeutics, Yakult Honsha Co. Ltd., Chr. Hansen Holding A/S, Lallemand Inc., Lifeway Foods Inc., BioGaia AB, Probi AB, Seed Health, Enterome, Vedanta Biosciences Inc., Evolve BioSystems Inc., Winclove Probiotics B.V., Kallyope Inc., Sun Genomics Inc., Synlogic Inc., OpenBiome, and Codex Labs Corp.

North America was the largest region in the gut microbiota market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gut microbiota report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gut microbiota market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gut microbiota market consists of sales of postbiotics, personalized nutrition products, and fecal microbiota transplantation (FMT) preparations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gut Microbiota Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gut microbiota market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for gut microbiota ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gut microbiota market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Gut Microbiota Market Characteristics

3. Gut Microbiota Market Trends And Strategies

4. Gut Microbiota Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gut Microbiota Growth Analysis And Strategic Analysis Framework

6. Gut Microbiota Market Segmentation

7. Gut Microbiota Market Regional And Country Analysis

8. Asia-Pacific Gut Microbiota Market

9. China Gut Microbiota Market

10. India Gut Microbiota Market

11. Japan Gut Microbiota Market

12. Australia Gut Microbiota Market

13. Indonesia Gut Microbiota Market

14. South Korea Gut Microbiota Market

15. Western Europe Gut Microbiota Market

16. UK Gut Microbiota Market

17. Germany Gut Microbiota Market

18. France Gut Microbiota Market

19. Italy Gut Microbiota Market

20. Spain Gut Microbiota Market

21. Eastern Europe Gut Microbiota Market

22. Russia Gut Microbiota Market

23. North America Gut Microbiota Market

24. USA Gut Microbiota Market

25. Canada Gut Microbiota Market

26. South America Gut Microbiota Market

27. Brazil Gut Microbiota Market

28. Middle East Gut Microbiota Market

29. Africa Gut Microbiota Market

30. Gut Microbiota Market Competitive Landscape And Company Profiles

31. Gut Microbiota Market Other Major And Innovative Companies

32. Global Gut Microbiota Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gut Microbiota Market

34. Recent Developments In The Gut Microbiota Market

35. Gut Microbiota Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기